About Dendreon
Dendreon is a biotechnology company focused on innovative cancer therapies. We are dedicated to the research and development of personalized treatments that empower patients with actionable options against cancer. Our flagship product, Provenge, is the first FDA-approved cancer immunotherapy for prostate cancer, and it has paved the way for further advancements in the field.
At Dendreon, we continue to invest in scientific research, clinical trials, and new treatment modalities to improve patient outcomes. Our team is passionate about pushing the boundaries of science to enhance the lives of individuals battling cancer. By leveraging cutting-edge technology and a commitment to innovation, we strive to redefine the future of cancer care.
FAQs
- Which countries does Dendreon have remote employees in?
- Dendreon has employees in United States.
- When was Dendreon founded?
- Dendreon was founded in 1992.
- Who is the CEO of Dendreon?
- Mark D. Brouckman is the CEO of Dendreon.
- How many employees does Dendreon have?
- Dendreon has 201-500 employees.
- What industries or markets does Dendreon operate in?
- Dendreon operates in the following markets: Cancer Treatment, Immunotherapy, Healthcare, Life Sciences, Oncology, Medical Research, Clinical Trials, Biotech, Precision Medicine, and Pharmaceutical.
- What is Dendreon's website?
- Dendreon's website is dendreon.com.